Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modification to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Asset sale to CorMedix: $145.0M cash plus 14,583,333 CorMedix shares, transferring substantially all operating assets and liabilities.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Asset sale to CorMedix: $145.0M cash plus 14,583,333 CorMedix shares, transferring substantially all operating assets and liabilities
- Additional contingent value: 5.0% royalties above $25.0M annual sales, plus ZYNRELEF earn-outs of $25.0M and $30.0M
- Heron plans to repay its working-capital facility, then pursue acquisitions, investments and other strategic uses of retained cash, NOLs and securities
- Closing requires Heron stockholder approval, antitrust clearance and other conditions, with a six-month outside date and $4.0M termination fee exposure
- Stockholders owning approximately 22% signed voting agreements supporting the transaction; Rubric may exchange $35.0M of notes for CorMedix shares after closing
Item 3.03 · Material Modification to Rights of Security Holders
- Amendment No. 2 to the Tax Benefit Preservation Plan modifies security-holder rights
- The amendment’s specific terms appear under Item 1.01 and determine the practical shareholder impact
- Tax-preservation plans typically seek to protect HRTX’s tax attributes from ownership changes
Item 7.01 · Regulation FD Disclosure
- Joint press release announces Purchase Agreement for Buyer’s acquisition of substantially all HRTX assets
- Proposed transaction requires HRTX stockholder approval and regulatory clearances before closing
- HRTX expects to receive Buyer common stock issued through a private placement
- Post-closing HRTX may have limited operations, with plans potentially focused on monetizing Buyer shares and using NOLs
- Key investor risks: transaction failure, Buyer-share dilution or decline, termination fees, and Nasdaq compliance challenges
Item EX-99.1 · Exhibit EX-99.1
- CorMedix to acquire substantially all Heron assets for $145M cash plus 14,583,333 shares, approximately $222.6M upfront value
- Portfolio adds four commercial products and approximately $150M trailing-twelve-month net product revenue
- CorMedix projects $45M-$60M annual operating synergies and immediate earnings and free-cash-flow accretion
- Financing includes $75M initial draw from a new $150M Pharmakon term loan, with another $75M tranche available
- Closing targeted for Q1 2027, subject to Heron stockholder approval and regulatory clearance; Heron remains publicly traded with approximately $2.3B NOLs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.